Victor Nwanguma, MD
Infectious Disease · Bend, ORNPI 1366601387
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,200 of the $1,710 with a category attached, or 70.2%. Gilead accounts for 75.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $1,200 and has fallen 82.3% since, to $213 in 2025. Among infectious disease clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $131.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Pfizer$136
- AbbVie$128
- Aimmune Therapeutics, Inc.$77
- Merck$33
- Insmed, Inc.$16
- plus $35 from 3 others
What the payments were for
- Consulting fees$1,20070%
- Food & beverage$49429%
- Education$161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 2 | $1,285 |
| Pfizer | 1 | $136 |
| AbbVie(2 entities) | 3 | $128 |
| Aimmune Therapeutics, Inc. | 1 | $77 |
| Merck | 2 | $33 |
| Insmed, Inc. | 1 | $16 |
| Viiv Healthcare Company | 1 | $14 |
| Novo Nordisk | 1 | $12 |
| Bio Products Laboratory USA, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,710 in reported general payments places this provider in the 90th percentile of 90 infectious disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 130 | $528,761 |
| EpclusaSofosbuvir/Velpatasvir | 13 | $314,518 |
| DovatoDolutegravir Sodium/Lamivudine | 29 | $110,523 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 30 | $94,191 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $54,754 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $44,380 |
| TivicayDolutegravir Sodium | 19 | $42,491 |
| Oxacillin Sodium | 16 | $13,260 |
| Fosfomycin Tromethamine | 95 | $9,127 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 11 | $2,687 |
| Cephalexin | 65 | $2,319 |
| Doxycycline Hyclate | 56 | $2,159 |
| ValacyclovirValacyclovir Hcl | 19 | $1,422 |
| CeftriaxoneCeftriaxone Sodium | 18 | $1,205 |
| Fluconazole | 13 | $1,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Epclusa, Descovy | $1,285 | $887,659158 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $14 | $153,01448 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 infectious disease providers in Oregon.
Other infectious disease in Bend
- Jon LutzBend$138
- Carmen ShererBend$124
- Laurie D'avignonBend$104
- Emma ConsidineBend$33
- Cynthia MareeBend$16
- Laura SelbyBend$15
- Kevin WinthropPortland$1.8M
- Tobias PuschPortland$208K
- Wendi DrummondPortland$128K
- David GilbertPortland$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.